ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.

Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.

The ODYSSEY-HCM study was a randomised, double-blind, placebo-controlled trial examining mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). This parallel assignment study evaluated specified doses of mavacamten against placebo over 48 weeks, with primary outcome measures including change from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO2) at Week 48.

Findings showed no significant differences in the primary endpoint with mavacamten compared to placebo at 48 weeks.

Interview Questions:

1. What was the rationale behind ODYSSEY-HCM?
2. What was the study design and patient population?
3. What were your key findings?
4. How might these results change the treatment landscape for patients with non-obstructive hypertrophic cardiomyopathy?
5. What are the next steps for mavacamten development in this patient population based on these ODYSSEY-HCM results?

Recorded on-site at ESC Congress 2025, Madrid.

Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.